{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-257688","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.031682+00:00","generated_at":"2026-06-23T05:38:43.168085+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunovant prices $75M stock offering at $6/share to fund IMVT-1402 development","bullets":["Priced 12.5M shares at $6.00 per share; gross proceeds ~$75M before discounts.","Investors include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF, and Commodore Capital.","Net proceeds to accelerate IMVT-1402 development, including a proposed pivotal trial.","Existing cash plus offering proceeds expected to fund company into H2 2025.","Offering expected to close Oct 6, 2022; SVB Securities and Truist Securities are joint bookrunners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-257688","json":"https://secwatch.observer/filing/0001193125-22-257688.json","markdown":"https://secwatch.observer/filing/0001193125-22-257688.md","text":"https://secwatch.observer/filing/0001193125-22-257688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000119312522257688/0001193125-22-257688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000119312522257688/d391688d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:38:43.168085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}